Indoco Remedies launches FEVINDO : 400 mg Favipiravir


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ indoco-remedies-launches-favipiravir-fevindo-400-mg
Now Indoco joins Favipiravir production with 400mg tablets

(Favipiravir) 400 mg Tablets in India. Fevindo - 400 (Favipiravir) is an antiviral drug, effective against the RNA-based influenza virus. The drug has been approved by DCGI in the treatment of Covid-19. Fevindo 400 reduces pill burden by 50% and ensures convenient dosing and better patient compliance.

Ms. Aditi Kare Panandikar, Managing Director - Indoco Remedies Ltd. commented, “The Covid-19 crisis has created a vast disruption to life in India and all over the globe. As part of the pharma industry, we have been able to do our bit in the prevention of Covid-19 with our brands Karvol Plus, ATM, Febrex Plus and Rexidin SRS Mouthwash. With the launch of FEVINDO, we are taking the next step from prevention to the treatment of Covid-19.”

Fevindo - 400 (Favipiravir) will be made available at all government approved COVID care centres and selected medical practitioners across the country. In addition to Fevindo, Indoco has two more new products for launch in Covid Care range, i.e., Povidone Iodine Gargle and Immunity booster chewable tablets with Zinc, Vitamin C and Vitamin D. Indoco has always been committed to providing quality medicines at affordable prices and with the launch of these products, the Company is all set to venture into the treatment of Covid-19.

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma company with presence in 55 countries. Indoco, a USD 145 million Company, employs over 5500 people including more than 300 skilled scientists. The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,00,000 doctors belonging to various specialities.

Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal,

Tags : #IndocoRemedies #FavipiravirLaunch #IndocoFavipiravir #FevindoFavipiravir #latestFavipiravirNewsSep28 #latestPharmaNewsSep28

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

The Future of Indian MedTech Exports: Can India Compete With Global Leaders?September 17, 2026
Robotic-Assisted Procedures Beyond Surgery: Where Is Automation Going Next in Healthcare?September 17, 2026
58 Students from SRM Medical College Selected for Union Government Research Programmes and Grants September 16, 2026
Handpickd Questions the Role of Science in Food with ‘Science-Less’ Newspaper CampaignSeptember 16, 2026
As Women’s Cancer Burden Rises, Integrated Care Emerges as The Next Frontier in Cancer TreatmentSeptember 16, 2026
Odia Superstar Babushaan Mohanty Inaugurates Manoj Das Library at Utkal Gaurav International SchoolSeptember 16, 2026
Yashoda Hospitals, Somajiguda Successfully Treats 10-Month-Old with Complex Heart Condition Through Staged ApproachSeptember 16, 2026
Tracky launches 16D, India's first 16-day continuous glucose monitoring system (CGM)September 16, 2026
Why Local Medical Device Manufacturing Matters for Indian HealthcareSeptember 16, 2026
Next-Generation Surgical Robots Entering the Indian Market: What It Means for Patients and ProvidersSeptember 16, 2026
ShardaCare - Healthcity Marks World Sepsis Day with Training for Over 50 NursesSeptember 15, 2026
From Empowerment to Ownership: Upasana Kamineni Konidela Calls for a BRICS Women’s Economic CorridorSeptember 15, 2026
WORLD HEART DAY 2026: Don't Miss a Beat: The Heart Attacks That Never Had to HappenSeptember 15, 2026
BL Agro Announces Investment of ₹1,500 Crore In Its Biotech-Arm Leads Genetics To Build An Integrated Dairy and Genetics EcosystemSeptember 15, 2026
Can You Have PMOS With Regular Periods? What Women Often Get WrongSeptember 15, 2026
Hospital Data Breaches in India: What Every Patient Needs to Know Right NowSeptember 15, 2026
Cybersecurity of ICUs: Protecting Connected Critical-Care Systems in Indian HospitalsSeptember 15, 2026
Fortis Hospital, Shalimar Bagh Becomes Delhi NCR’s First Multi-speciality Hospital to Launch Rezūm™ Water Vapor Therapy for Enlarged ProstateSeptember 14, 2026
Dr. Reddy's Laboratories Launches Nationwide Educational Initiative to Strengthen India's Obesity Care WorkforceSeptember 14, 2026
IIM Bodh Gaya Hosts Convergence 3.0: The Next Frontier of Healthcare SectorSeptember 14, 2026